Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.04

€3.04

9.100%
0.258
9.100%
-
 
28.03.24 / Tradegate WKN: A111X8 / Name: Aldeyra / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Aldeyra Therapeutics Inc. Stock

A very strong showing by Aldeyra Therapeutics Inc. today, with an increase of €0.26 (9.100%) compared to yesterday's price.
Our community identified positive and negative aspects for Aldeyra Therapeutics Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Aldeyra Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.

Pros and Cons of Aldeyra Therapeutics Inc. in the next few years

Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Aldeyra Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Aldeyra Therapeutics Inc. 9.100% 13.453% -10.968% -63.926% -6.527% - -
Salarius Pharmaceuticals Inc. 2.420% -18.824% -22.617% -76.389% -25.405% -98.665% -99.992%
Ardelyx Inc. -1.160% -6.371% -22.654% 73.980% 16.955% 25.791% -
Evolus Inc -0.770% 2.362% -2.985% 66.667% 39.037% 31.287% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-01

General Impressions on Financials

A cursory glance at the financials of the Biotechnology & Medical Research industry stalwart, Aldeyra, reveals a mixed bag. The balance sheets show an upward trend in their total assets over the years. From 83 million in 2020, their total assets rose exponentially to 233 million in 2021, tapering off slightly to 181 million in 2022. Although declining in the recent year, the overall upward trajectory in assets reflects a positive signal, indicative of the company's ability to increase its asset base.

However, delving into the financial health of Aldeyra offers a contrasting picture. The company's net income has consistently been in the negative over the past three years, indicating that the company is not turning a profit. The EBIT value is persistently negative as well, implying that the firm is facing operational challenges and struggling to control its operating costs. Moreover, the company seems to heavily rely on external funding to finance its growth as suggested by its negative net debt, which points to the fact that the company has more cash than debt on its books.

Comments

Prediction Buy
Perf. (%) 46.74%
Target price 7.000
Change
Ends at 21.07.20

Buy with target price 7.0
Show more